4/9/2013

Gilead Sciences filed a new drug application with the FDA for sofosbuvir, an oral nucleotide analogue, to treat chronic hepatitis C virus infection. The firm seeks to use sofosbuvir in combination with existing treatments ribavirin and pegylated interferon in treatment-naive patients with genotype 1, 4, 5 and 6 infection. The drug is expected to be approved by year's end or early next year.

Related Summaries